

12-13-01

10/010 Ret'd PCT/PTO 29/001 2001

| | | | | | |
|--|--|---|--|---|--|
| FORM PTO-1390 (Modified) (Rev. 12-2000) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTORNEY'S DOCKET NUMBER NIDN-10427 | |
| TRANSMITTAL LETTER TO THE UNITED STATES | | | | U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR To be assigned 10/018018 | |
| DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | | | | |
| INTERNATIONAL APPLICATION NO PCT/GB00/01963 | | INTERNATIONAL FILING DATE May 22, 2000 | | PRIORITY DATE CLAIMED May 21, 1999 | |
| TITLE OF INVENTION Method of Magnetic Resonance Imaging | | | | | |
| APPLICANT(S) FOR DO/EO/US Karen Briley-Saebo, Atle Bjornerud, Daniel Nanz, and Dominik Weishaupt | | | | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | | | |
| <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). | | | | | |
| Items 13 to 20 below concern document(s) or information included: | | | | | |
| <ol style="list-style-type: none"> 13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: copy of this transmittal letter for charging purposes return postcard | | | | | |

| | | |
|--|---|---|
| U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.101) 10/018018 To be assigned | INTERNATIONAL APPLICATION NO. PCT/GB00/01963 | ATTORNEY'S DOCKET NUMBER NIDN-10427 |
|--|---|---|

24. The following fees are submitted:

| | | | |
|--|---------------------|---------------------|------------------------------|
| BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : | | CALCULATIONS | PTO USE ONLY |
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO | \$1040.00 | | |
| <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO | \$890.00 | | |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$740.00 | | |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) | \$710.00 | | |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) | \$100.00 | | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | \$890.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)). | | \$0.00 | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE |
| Total claims | 13 - 20 = | 0 | x \$18.00 |
| Independent claims | 2 - 3 = | 0 | x \$84.00 |
| Multiple Dependent Claims (check if applicable). <input type="checkbox"/> | | | \$0.00 |
| TOTAL OF ABOVE CALCULATIONS = | | | \$890.00 |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. | | | \$0.00 |
| SUBTOTAL = | | | \$890.00 |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). | | | \$0.00 |
| TOTAL NATIONAL FEE = | | | \$890.00 |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/> | | | \$0.00 |
| TOTAL FEES ENCLOSED = | | | \$890.00 |
| | | | Amount to be refunded |
| | | | \$ |
| | | | charged |
| | | | \$ |

a. ☐ A check in the amount of _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 500-588 in the amount of \$890.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 500-588 A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Royal N. Ronning, Jr.
Amersham Biosciences
800 Centennial Avenue
Piscataway, New Jersey 08855

(732) 457-8423


 SIGNATURE

Royal N. Ronning, Jr.
 NAME

32,529
 REGISTRATION NUMBER

October 29, 2001
 DATE

1001130113, 70123012
10/018018

JC19 Rec'd PCT/PTO 29 OCT 2001

NIDN-10427

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------|--------------------------------------|-----------------|----------------|
| Application of: | K. Briley-Saebo, et al. | Group Art Unit: | To be assigned |
| Serial Number: | To be assigned | Examiner: | To be assigned |
| Filing Date: | October 29, 2001 | | |
| Title: | Method of Magnetic Resonance Imaging | | |

FIRST PRELIMINARY AMENDMENT

Honorable Assistant Commissioner of Patents
Box Patent Application
Washington, D.C. 20231

Sir:

Please consider the following amendments and remarks in connection with the prosecution of the captioned application, which is a filing under 35 U.S.C. § 371 and claims priority to international application number PCT/GB00/01963 filed May 22, 2000. This application also claims priority to patent applications filed in Great Britain assigned number 9911937.2 filed May 21, 1999 and 0007869.1 filed March 31, 2000.

In the Claims

Please amend page 18, line 1, as follows:

[Claims]

What is claimed is:

Please amend claim 1 as follows:

1. (once amended) [A]In a method of interventional or intraoperative MRI wherein an invasive device is inserted into the vasculature of a human or non human animal (e.g. mammalian, avian, or reptilian) body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering a contrast agent into the vasculature of said body either by direct injection of the contrast agent through said device or by i.v. injection of the contrast agent directly into the patient whereby to facilitate visualisation of said device in said image.

Please amend claim 2 as follows:

2. (once amended) [A]The method of claim 1 wherein said contrast agent is a blood pool contrast agent.

Please amend claim 3 as follows:

3. (once amended) [A]The method [as claimed in claims 1 or claim 2]of claim 1 wherein [the]a difference in at least one parameter chosen from T_1 , T_2 and T_2^* between the blood and said device is utilised to generate image contrast between the blood and said device.

Please amend claim 4 as follows:

4. (once amended) [A]The method [as claimed in any of claims 1 to 3]of claim 1 wherein said device is filled with a diamagnetic material or a paramagnetic material.

Please amend claim 5 as follows:

5. (once amended) [A]The method [as claimed in any of claims 1 to 4]of claim 1 wherein said contrast agent enhances [the]T₁ and/or T₂* relaxation properties of the blood relative to that of said device.

Please amend claim 6 as follows:

6. (once amended) [A]The method [as claimed in]of claim 5 wherein; the T₁ relaxation property of the blood is enhanced relative to that of said device; [and wherein]T₁-weighted sequences are used; and said device is filled with diamagnetic material so that the blood appears bright in said image, relative to said device.

Please amend claim 7 as follows:

7. (once amended) [A]The method [as claimed in]of claim 5 wherein; the T_2^* relaxation property of the blood is enhanced relative to that of said device; [and wherein] T_2^* -weighted sequences are used; and said device is filled with paramagnetic material so that said device appears bright in said image, relative to the blood.

Please amend claim 8 as follows:

8. (once amended) [A]The method [as claimed in any of claims 1 to 7]of claim 2 wherein said contrast agent is magnetic iron oxide blood pool contrast agent.

Please amend claim 9 as follows:

9. (once amended) [A]The method [as claimed in any of claims 1 to 8]of claim 1 wherein said contrast agent comprises superparamagnetic iron oxide particles having on their surfaces degraded starch[and optionally a material which inhibits opsonization].

Please add new claim 13 as follows:

13. (new) The method of claim 9 wherein said contrast agent includes a material to inhibit opsonization.


Remarks

Claims 1-12 are pending in the instant application. Applicants have amended claims 1-12 to more fully conform with U.S. practice and to delete multiple dependencies. Applicants have also added new claim 13. A version of the claims marked up to show the amendments, as well as a clean version of the claims encompassing the amendments, is attached hereto.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry.

Applicants believe that the claims, as amended, are in allowable form, and earnestly solicit the allowance of claims 1-13.

Respectfully submitted,



Royal N. Ronning, Jr. 32,529
Attorney for Applicants

Amersham Biosciences
800 Centennial Avenue
P. O. Box 1327
Piscataway, New Jersey 08855-1327

Tel: (732) 457-8423
Fax: (732) 457-8463

H:\DEPT\Law_Dept\IP Dept\Amendments\First Preliminary Amendment-NIDN10427 (10-29-01).doc

Claims (marked-up version showing amendment(s))

Page 18, line 1:

[Claims]

What is claimed is:

1. (once amended) [A]In a method of interventional or intraoperative MRI wherein an invasive device is inserted into the vasculature of a human or non human animal (e.g. mammalian, avian, or reptilian) body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering a contrast agent into the vasculature of said body either by direct injection of the contrast agent through said device or by i.v. injection of the contrast agent directly into the patient whereby to facilitate visualisation of said device in said image.
2. (once amended) [A]The method of claim 1 wherein said contrast agent is a blood pool contrast agent.
3. (once amended) [A]The method [as claimed in claims 1 or claim 2]of claim 1 wherein [the]a difference in at least one parameter chosen from T_1 , T_2 and T_2^* between the blood and said device is utilised to generate image contrast between the blood and said device.

4. (once amended) [A]The method [as claimed in any of claims 1 to 3]of claim 1 wherein said device is filled with a diamagnetic material or a paramagnetic material.
5. (once amended) [A]The method [as claimed in any of claims 1 to 4]of claim 1 wherein said contrast agent enhances [the]T₁ and/or T₂* relaxation properties of the blood relative to that of said device.
6. (once amended) [A]The method [as claimed in]of claim 5 wherein; the T₁ relaxation property of the blood is enhanced relative to that of said device; [and wherein]T₁-weighted sequences are used; and said device is filled with diamagnetic material so that the blood appears bright in said image, relative to said device.
7. (once amended) [A]The method [as claimed in]of claim 5 wherein; the T₂* relaxation property of the blood is enhanced relative to that of said device; [and wherein]T₂*-weighted sequences are used; and said device is filled with paramagnetic material so that said device appears bright in said image, relative to the blood.
8. (once amended) [A]The method [as claimed in any of claims 1 to 7]of claim 2 wherein said contrast agent is magnetic iron oxide blood pool contrast agent.

9. (once amended) [A]The method [as claimed in any of claims 1 to 8]of claim 1 wherein said contrast agent comprises superparamagnetic iron oxide particles having on their surfaces degraded starch[and optionally a material which inhibits opsonization].
10. (once amended) [A]The method [as claimed in any of claims 1 to 9]of claim 1 wherein said device is [chosen]selected from the group consisting of catheters, balloons, optical fibres, guide wires, needles, biopsy needles, electrodes, electrode leads, implants, stents and stent grafts.
11. (once amended) [A]The method [as claimed in any of claims 1 to 10]of claim 1 wherein said device is not marked with a magnetic susceptibility agent.
12. (once amended) [The]In a method for use of a blood pool MR contrast agent for the manufacture of a parenterally administrable MR contrast medium for use in a method of surgery or therapy wherein an invasive device is inserted into the vasculature of a human or non human animal body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, [said method also]the improvement comprising administering said contrast medium into the vasculature of said body whereby to facilitate visualisation of said device in said image.

13. (new) The method of claim 9 wherein said contrast agent includes a material to inhibit opsonization.

Claims (clean version encompassing amendments)

What is claimed is:

1. (once amended) In a method of interventional or intraoperative MRI wherein an invasive device is inserted into the vasculature of a human or non human animal (e.g. mammalian, avian, or reptilian) body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering a contrast agent into the vasculature of said body either by direct injection of the contrast agent through said device or by i.v. injection of the contrast agent directly into the patient whereby to facilitate visualisation of said device in said image.
2. (once amended) The method of claim 1 wherein said contrast agent is a blood pool contrast agent.
3. (once amended) The method of claim 1 wherein a difference in at least one parameter chosen from T_1 , T_2 and T_2^* between the blood and said device is utilised to generate image contrast between the blood and said device.
4. (once amended) The method of claim 1 wherein said device is filled with a diamagnetic material or a paramagnetic material.

5. (once amended) The method of claim 1 wherein said contrast agent enhances T_1 and/or T_2^* relaxation properties of the blood relative to that of said device.
6. (once amended) The method of claim 5 wherein: the T_1 relaxation property of the blood is enhanced relative to that of said device; T_1 -weighted sequences are used; and said device is filled with diamagnetic material so that the blood appears bright in said image, relative to said device.
7. (once amended) The method of claim 5 wherein: the T_2^* relaxation property of the blood is enhanced relative to that of said device; T_2^* -weighted sequences are used; and said device is filled with paramagnetic material so that said device appears bright in said image, relative to the blood.
8. (once amended) The method of claim 2 wherein said contrast agent is magnetic iron oxide blood pool contrast agent.
9. (once amended) The method of claim 1 wherein said contrast agent comprises superparamagnetic iron oxide particles having on their surfaces degraded starch.
10. (once amended) The method of claim 1 wherein said device is selected from the group consisting of catheters, balloons, optical fibres, guide wires, needles, biopsy needles, electrodes, electrode leads, implants, stents and stent grafts.

11. (once amended) The method of claim 1 wherein said device is not marked with a magnetic susceptibility agent.
12. (once amended) In a method for use of a blood pool MR contrast agent for the manufacture of a parenterally administrable MR contrast medium for use in a method of surgery or therapy wherein an invasive device is inserted into the vasculature of a human or non human animal body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering said contrast medium into the vasculature of said body whereby to facilitate visualisation of said device in said image.
13. (new) The method of claim 9 wherein said contrast agent includes a material to inhibit opsonization.

4/PRTS

100329301107018018

PCT/GB00/01963
JC19 Rec'd PCT/PTO 29 OCT 2001

- 1 -

Method of Magnetic Resonance Imaging

The invention relates to improvements in and relating to magnetic resonance imaging (MRI), in particular to generation of magnetic resonance images of invasive devices, e.g. during surgical procedures.

During surgical and therapeutic procedures it is frequently desirable for the physician to be able to locate or guide invasive devices inserted into the body (for example catheters, guide wires, biopsy needles, etc.) when these are not directly visible to the naked eye.

Due to the reduced invasiveness of surgical procedures, MRI-guided interventional procedures have gained increasing importance in recent years. Such MRI guided procedures can be divided into two categories: intraoperative procedures which integrate surgery with MRI and interventional procedures for guiding, monitoring and controlling therapy.

Intraoperative procedures generally require an open magnet MR imager and are desirable as the MRI can be used to define anatomy and monitor tissue function as it changes during surgery. By monitoring anatomy and function in this way, the clinical outcome for the patient may be improved since complications may be reduced by reducing the degree of invasiveness of the surgery.

Interventional procedures generally require only limited patient access and thus conventional closed magnet MR imagers may be used. The high spatial and temporal resolution available in MRI allows for accurate "near real time" guidance of devices such as catheters, guide wires, biopsy needles, etc.

The success of an MRI-guided interventional or intraoperative procedure generally depends on the ability of the MRI technique to provide sufficiently accurate visualisation of the instruments and devices

inserted into the patient's body. Currently, either active or passive visualisation techniques have been used for monitoring and visualising such instruments and devices (herein generally referred to as "invasive devices").

In active visualisation, the invasive device is provided with a small signal receiving antenna (e.g. on the tip of the device). The magnetic resonance signal from water protons in the vicinity of the antenna is detected by the antenna and incorporated into the MR image generated by the MR imager. The result is a "road map" showing the movement of the antenna (and hence the device) within the patient. There are however two problems associated with active visualisation. Firstly, heat generated within the antenna may be large if large magnetic field gradients or rapid gradient switching are used in the MRI procedure. Secondly, since the signal from the device is superimposed over the original MR image, any tissue movement may result in loss in accuracy of spatial information regarding device location.

The term "passive visualisation" is used to describe the case where device visualisation relies on a difference in magnetic susceptibility between the material from which the device is made and the surrounding biological tissue or fluid. In order to increase this susceptibility difference, it has been conventional to mark the device with a magnetic (i.e. paramagnetic, ferrimagnetic, ferromagnetic or superparamagnetic) material, such as for example dysprosium oxide (Dy_2O_3). To avoid extensive marking resulting in blurring artefacts in the MR images, it has been common to incorporate small bands or rings of Dy_2O_3 or of a material containing for example 10% w/w Dy_2O_3 . *In vitro* studies have shown that such Dy_2O_3 -marked devices can be visualised accurately in "near real time" imaging procedures without causing significant image

artefacts (such as for example blurring or distortion) as long as the device is parallel to the primary magnetic field of the MR imager. Where the device is perpendicular to the primary field however, blurring and distortion artefacts occur which result in over-estimation of device size and decrease in spatial resolution.

Biopsy needles are currently monitored using passive visualisation; however the needles currently used produce severe image artefacts which distort the observed size and location of the needles. To compensate for this, two techniques have been developed. Firstly a laser guidance system may be used to guide the needle to the target tissue; however, using this technique, it is still difficult to determine needle depth within the tissue. Accordingly, needles have been produced which have a small inner bore at the needle tip. This is filled with a gadolinium chelate solution (e.g. a solution of Gd DTPA, Gd DTPA-bismethylamide or Gd HP-DO3A) which allows for visualisation of the needle tip in the MR image. However the gadolinium chelates used distribute rapidly into the extracellular space and thus even with single or multiple injections of the gadolinium chelate solution only temporary assistance in passive visualisation of the needle tip is achieved.

The present invention is directed to facilitating passive visualisation of invasive devices and relies instead on introducing into the vasculature a blood pool MR agent, i.e. an MR contrast agent which does not distribute into the extracellular space but instead remains substantially in the intravascular space during the time course of the visualisation procedure. The effect of the contrast agent is to enhance the relaxation properties of the blood (i.e. to reduce T_1 and/or T_2^* for blood) relative to those of the invasive device. Thus, using the invention, the invasive devices traditionally utilised in intraoperative and

- 4 -

interventional MRI can be used.

Thus viewed from one aspect the invention provides a method of interventional or intraoperative MRI wherein an invasive device is inserted into the vasculature of a human or non human animal (e.g. mammalian, avian or reptilian) body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering into the vasculature of said body by either direct injection of the contrast agent through said device or by i.v. injection of the contrast agent directly into the patient whereby to facilitate visualisation of said device in said image.

Viewed from a further aspect the invention provides the use of a blood pool MR contrast agent for the manufacture of a parenterally administrable MR contrast medium for use in a method of surgery or therapy wherein an invasive device is inserted into the vasculature of a human or non human animal (e.g. mammalian, avian or reptilian) body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, said method also comprising administering said contrast medium into the vasculature of said body whereby to facilitate visualisation of said device in said image.

By a blood pool MR contrast agent is meant a magnetic (e.g. paramagnetic, ferromagnetic, ferrimagnetic or superparamagnetic) material capable of reducing the T_1 and/or T_2^* of water protons and which if administered into the vascular space does not significantly leak out into the interstitium during the time course of the interventional or intraoperative procedure, i.e. it is essentially confined to the vascular space until excreted or metabolized. Examples of such blood pool agents include polymeric chelates (e.g. cascade polymers or dendrimers carrying metallated chelate groups) and particulates, in particular iron

oxides and liposomes. Generally the agent should have a blood half life of at least 5 minutes, preferably at least 30 minutes. By way of contrast, the first parenteral MR contrast agents Gd DTPA (Magnevist® from Schering), Gd DTPA-bismethylamide (Omniscan® from Nycomed Amersham) and Gd HP-D03A (ProHance®) are all extracellular fluid MR agents; they are water-soluble mono-chelates which following administration into the vasculature rapidly extravasate into the interstitium.

Blood pool agents of particular use in the method of this invention include low molecular weight chelates which bind to blood proteins, e.g. blood proteins such as albumin, for example DTPA or DOTA derivatised with protein binding groups, e.g. lipophilic side chains such as aromatic moieties, e.g. one or more phenyl ring systems. One such example is MS-325/Angiomark of EPIX.

Suitable polymer based contrast agents for use in the method of the present invention can be carbohydrate or protein based, e.g. CMD-DTPA-Gd of Guerbet (Carboxymethyl dextran-GdDTPA conjugates), GdDTPA polylysine conjugates, or cascade or dendrimer polymers, e.g. Gadomer 17 of Schering AG or similar cascade polymers as described in US-A-5874061 (of Schering AG), herein incorporated by reference.

Suitable iron oxide (or doped iron oxide) based contrast agents for use in the method of the present invention are known in the field under the name of SPIO (superparamagnetic iron oxides) or USPIO (ultrasmall superparamagnetic iron oxides). Examples include carbohydrate stabilised iron oxide particles, e.g. dextran-stabilised particles such as Combidex of Advanced Magnetics, and NC100150 (Clariscan, Nycomed Amersham).

More particularly the magnetic iron oxide contrast agent is preferably a water-dispersible material comprising magnetic iron oxide particles having on their surfaces (e.g. as a coating), an optionally modified

carbohydrate or polysaccharide or derivative thereof, e.g. a glucose unit containing optionally modified polysaccharide or derivative thereof, preferably an optionally modified dextran or starch or derivative thereof, for example a cleaved (e.g. oxidatively cleaved) starch or carboxylated dextran. Such iron oxide complexes preferably also comprise a further material (e.g. coating material), especially one which inhibits opsonization, e.g. a hydrophilic polymer, preferably a functionalized polyalkylene oxide, more preferably a functionalized polyethylene glycol (PEG), in particular methoxy PEG phosphate (MPP).

The iron oxide complexes preferably have a core (i.e. iron oxide particle) diameter (mode diameter) of 1 to 15 nm, more preferably 2-10 nm, especially 3-7 nm, a total diameter (mode particle size) of 1 to 100 nm, more preferably 5-50 nm, especially preferably 10-25 nm, an r_2/r_1 ratio at 0.47T and 40°C of less than 3, more preferably less than 2.3, still more preferably less than 2.0, especially preferably less than 1.8. The saturation magnetization (Msat) at 1T is preferably 10 to 100 emu/gFe, more preferably 30-90 emu/gFe.

Other particulate based systems of use in the method of the present invention include liposomal or emulsion based agents.

Furthermore, compound 7228 of Advanced Magnetics can be used in the method of the present invention, as can the materials described in WO 91/12025, WO 90/01899, WO 88/00060, WO 91/12526 and WO 95/05669, all to Advanced Magnetics, and those described in WO92/11037 and WO90/01295, all of which publications are incorporated herein by reference.

Using blood pool MR contrast agents which remain in the vascular space during the MRI-guided procedure allows for extensive monitoring of the invasive device during the procedure. The method of the invention, an "induced passive visualisation" technique, not only

allows visualisation of static devices, such as stents, but also can be used to guide placement of devices, e.g. it can be used in ablation therapy to mark vessels and/or aid in the placement of the ablation device.

Currently, three types of ablation procedures are in use clinically: interstitial laser-induced thermotherapy (LITT); focussed ultrasound; and rf-ablation.

LITT is used for the destruction of local tumors in solid organs - laser light is delivered to the tumor through optical fibres and tumor destruction occurs by direct heating by the laser light. The optical fibre is introduced in MRI-guided procedures using an MRI-guided catheter; induced passive visualisation according to the invention will allow accurate visualisation of the catheter and ensure correct placement of the optical fibre tip.

During MRI-guided focussed ultrasound ablation therapy, an ultrasound transducer is moved hydraulically across the patient and the depth and position of the ultrasound focus are determined by laser optical fibres which are locked onto target from an MR image. Induced passive visualisation according to the invention will assist by increasing the accuracy of the focus positioning since the technique allows for monitoring of all major vessels surrounding the tumor, as well as of the tumor itself, throughout the procedure.

In rf-ablation therapy, a radiofrequency electrode is placed in tissue which has previously been injected with saline. The tissue around the electrode is then heated by applying 1500-1600 mA to the electrode. The technique is relatively non-specific since treatment regions vary in shape and are dependent on local saline concentration; induced passive visualisation according to the invention will increase specificity by allowing more accurate placement of the electrode and more accurate estimation of saline concentration. Again,

both tumor and surrounding vessels may be monitored throughout the procedure.

During all intraoperative and interventional procedures, complications due to bleeding increase the risks associated with the procedures. Induced passive visualisation according to the invention however allows for accurate monitoring and assessment of bleeding during the procedure. Since the blood pool MR contrast agent remains in the blood during the procedure, any damage to blood vessels that causes changes in vessel permeability can be observed.

The invasive devices which can be monitored according to the invention include, but are not limited to, catheters, balloons, optical fibres, guide wires, needles (e.g. biopsy needles), electrodes, electrode leads, implants, stents and stent graphs. Generally these devices will be diamagnetic and exhibit long T_1 values. If desired, the devices may be marked with a magnetic susceptibility agent, e.g. bands or strips containing dysprosium oxide - however such marking is not necessary and desirably is avoided. As in all MRI-guided procedures however the devices used are preferably not substantially ferromagnetic or ferrimagnetic as this will cause image defects and gradient switching may cause unwanted motion of the devices.

The MR imaging procedure used in the method of the invention may for example be any conventional MRI procedure, e.g. T_1 or T_2^* weighted spin echo or gradient echo sequences. However, fast imaging procedures, such as gradient echo and echo planar imaging procedures are preferred. In a particularly preferred embodiment of the method of the invention, the imaging procedure involves administration of an iron oxide blood pool MR contrast agent, gradient echo imaging using small flip angles (e.g. 10 to 45°) and short echo times (e.g. 0.5 to 5 ms) and using larger flip angles (e.g. 55 to 75°)

and longer echo times (e.g. 6 to 20 ms). In the larger flip angle/longer echo time images the signal from the contrast agent containing blood is diminished and, using both images, visualisation of the invasive device may be facilitated (especially where the device contains a gadolinium chelate solution as a marker).

Viewed from another aspect the invention provides a method of interventional or intraoperative MRI wherein an invasive device is inserted into the vasculature of a human or non human animal body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering into said body a contrast agent which remains in the vasculature during the time course of said method so that the difference in T_1 and/or T_2 and/or T_2^* between the blood and said device containing a paramagnetic or diamagnetic material may be utilized to generate image contrast between blood and said device.

By containing it is meant that the device may contain the paramagnetic or diagnostic material when it is inserted or that the material may be placed in the device following its insertion.

Thus the method may involve administering a blood pool contrast agent (e.g. an USPIO) into the vasculature and filling an invasive device (before or after its insertion) with a paramagnetic agent (e.g. a gadolinium chelate) and then generating an image of the vasculature using very fast, heavily T_1 -weighted sequences. In this way slice position matching with the device is unnecessary. The selectivity of differentiation between blood and device is achieved by a minor increase in echo time that would not normally result in the sequence being termed non- T_1 -weighted.

Viewed from a further aspect the invention also provides methods of interventional or intraoperative MRI wherein an invasive device is inserted into the

vasculature of a human or non human animal (e.g. mammalian, avian or reptilian) body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, the improvement comprising administering into said body a contrast agent which remains in the vasculature during the time course of said method so that the T_1 and/or T_2^* of the blood is enhanced relative to that of said device, and wherein when enhancing the T_1 of the blood relative to said device, T_1 -weighted sequences should be used and said device should be filled with diamagnetic material (e.g. saline or medication) so that the blood appears bright relative to said device, and wherein when enhancing the T_2^* of the blood relative to the device, T_2 or T_2^* -weighted sequences should be used and the device coated with or filled with paramagnetic material (e.g. Gd complex or Mn complex) so that said device appears bright relative to the blood.

By initially or subsequently containing it is meant that the device may contain the paramagnetic chelate (preferably a water-soluble Gd or Mn monochelate) when it is inserted or that the chelate may be filled into the device following insertion.

In both the methods of the invention it is desirable to use as the blood pool MR contrast agent a superparamagnetic iron oxide, optionally coated with an opsonization inhibitor such as PEG, e.g. as described in WO97/25073. Such particles allow T_1 effects to predominate in heavily T_1 -weighted imaging sequences - leading to an increased signal intensity for blood relative to invasive device (i.e. a "bright blood" technique) - and allow T_2^* effects to predominate when T_2 -weighted imaging sequences are used - leading to a decreased signal intensity for blood relative to invasive device (i.e. a "black blood" technique). Such black blood techniques are used where paramagnetic

devices or devices with paramagnetic markers are used. The bright blood technique is used with diamagnetic devices which contain a diamagnetic material (e.g. saline or medication).

The dosage of the contrast agent used according to the invention will depend upon the species, the longitudinal relaxivity of the agent, the magnetic moment of the agent at the imaging field strength and the sequence parameters used to acquire the image. Desirably the blood pool MR contrast agent is administered at dosages sufficient to achieve T_1 values in blood, at steady state, of less than 300 ms, more preferably less than 200 ms and still more preferably less than 100 ms.

In MR procedures in which a blood pool contrast agent is to be administered into the vasculature, this would normally be done outside the region of interest for imaging, e.g. in a peripheral vein and one would not expect images of the catheter to be generated either on contrast agent administration or on contrast agent circulation (or recirculation) past the catheter. Thus in the methods of the invention the invasive device may be a catheter used for administration of the blood pool contrast agent; however more generally and preferably the invasive device will be other than a device through which the blood pool contrast agent is administered.

The blood pool contrast agent will preferably be administered by injection or infusion into the vasculature, for example infused over periods of 2 seconds to 5 minutes.

The contrast agent will desirably be formulated in a sterile aqueous medium, optionally containing further excipients such as pH modifiers, osmolality modifiers, chelating agents, etc.

The methods of the invention will now be described further with reference to the following non-limiting Examples and the accompanying drawings, in which:

Figure 1 shows the construction of two phantoms use to study the feasibility of catheter tracking by MRI;

Figure 2 shows a bright blood image of phantoms having catheters filled with saline (top) or 10mM Omniscan (bottom) and placed perpendicular to the applied field;

Figure 3 shows a bright blood image of phantoms having catheters filled with saline (left) or 10mM Omniscan (right) and placed parallel to the applied field;

Figure 4 shows a dark blood image of a phantom having a catheter filled with 10 mM Omniscan and placed perpendicular to the applied field;

Figure 5 shows a summary of an MRI signal optimisation study conducted at TR/TE=5.0/1.5 ms (Fig 5a) and TR/TE=18.0/9.0 ms (Fig 5b) with varying flip angles and concentrations;

Figure 6 shows spoiled GRE images of phantoms collected with parameters TR/TE/FA=5.2/1.2/40° (Fig 6a) and TR/TE/FA=18/9.0/70° (Fig 6b); and;

Figure 7 shows spoiled GRE in vivo images of the abdomen of a pig collected with parameters TR/TE/FA=5.2/1.2/40° (Fig 7a) and TR/TE/FA=18/9.0/70° (Fig 7b).

An aqueous suspension superparamagnetic iron oxide MR contrast agent, prepared according to the description of Example 12 of WO 97/25073 was used in these Examples.

The characteristics of the suspension were as follows:

[Fe] = 30.2 mg Fe/ml, density = 1.0589 g/ml, r_1 = 19.3 s⁻¹mM⁻¹, r_2 = 31.2 s⁻¹mM⁻¹, r_2/r_1 = 1.61, saturation magnetisation (Msat) = 84 emu/g Fe.

Example 1Phantom Study

A simple ex vivo phantom study was performed in order to assess the feasibility of performing induced passive catheter tracking by reducing T_1 and T_2^* of blood. Two phantoms were prepared by placing sections of a conventional interventional catheter (Pebax Souple 5F with inner diameter of 1.17 mm and outer diameter of 1.69 mm) into two plastic tubes of 10 mm diameter and 85 mm length inside 21 mm diameter, 60 mm length glass vials. The plastic tubes were fixed in the vial in a 2% agar gel containing gadolinium polymers (e.g. a gadolinium polychelate such as polylysinepolyDTPA.Gd) so that the T_1 of the gel at 40°C was 535 ms. The plastic tubes were filled with fresh human blood (Hct = 47%) containing sodium heparin. The iron oxide contrast medium was added to the blood so that the concentration of Fe added was 1.0 mM Fe (which is equivalent to a dose of 4 mg Fe/Kg bodyweight). One of the catheters was then filled with saline and sealed and the other catheter was filled with 10 mM Omniscan® (10 mM Gd DTPA-bismethylamide) and sealed. The arrangement was as shown in Figure 1 of the accompanying drawings. All imaging was performed at 1.5 T (Philips Gyroscan ACS-NT) using T_1 and T_2 -weighted 3D-gradient echo sequences (FFE). Table 1 shows the sequence parameters which were kept constant for all experiments.

Table 1: Pulse Sequence parameters for static *in vivo* phantom imaging

| Parameter | Value |
|-----------------|-----------|
| TR | 15.4 ms |
| Slice thickness | 0.7 mm |
| Field of view | 140 x 140 |
| Nmat | 256 x 256 |
| NEX | 2 |
| Flip angle | 30° |

The following two imaging series were performed on the phantoms:

Series 1: Phantoms placed perpendicular relative to the applied field. Images were acquired at echo times (TE) of 2 ms (for bright blood) and 12 ms (for black blood).

The phantoms were removed from the magnet and inverted several times to ensure the homogeneity of the blood samples prior to the on set of imaging Series 2.

Series 2: Phantoms placed parallel relative to the applied magnetic field. Images were acquired using a TE of 2 ms so that bright blood was obtained.

Figures 2, 3 and 4 of the accompanying drawings show the results obtained when either the T_1 (bright blood obtained using short echo times) or T_2^* (dark blood obtained using long echo times) of the blood is reduced relative to the device. In Figures 2 and 4 the phantoms were placed perpendicular relative to the applied magnetic field and Figure 3 shows the phantom placed parallel relative to the applied field. In Figures 2 and 3, short echo times were used so that the T_1 of the blood was reduced relative to that of the catheters. Figure 2 shows the phantoms placed perpendicular to the applied field. The catheters were filled with either

saline (top) and 10 mM Gd DTPA-BMA (bottom). In Figure 3, the phantoms were placed parallel to the applied magnetic field and the catheter containing the saline is shown to the left and the catheter containing the Gd DTPA-BMA is shown to the right. The diameter shown in these figures represents the total catheter diameter estimated by MRI. The actual catheter diameter for all phantoms was 1.69 mm.

The catheter filled with saline represents a conventional interventional catheter. The catheter filled with 10 mM Omniscan® represents an MRI catheter containing a paramagnetic tracer. The results clearly indicate the size of the catheter (total diameter) was underestimated when the catheter was filled with 10 mM Omniscan®. However, when the catheters were filled with saline (which represents a normal interventional procedure) fairly accurate estimates of size were obtained. The under-estimation of size observed when using a paramagnetic tracer is most likely due to the fact that the wall of the catheter has very few protons and consequently is not MR-visible. This means that the signal coming from the outer wall of the catheter is dark relative to the signal inside the catheter (which contains 10 mM Gd) and signal of the blood (which contains the iron oxide contrast medium). As a result, the size reflects only the inner-diameter of the catheter. However, when saline is used, a homogeneous dark signal is observed which accurately reflects catheter size. This is due to the fact that the catheter and the saline filling the catheter both appear hypointense relative to the blood containing the iron oxide contrast medium (bright blood obtained using short echo times).

No artefacts were observed for either phantom in any orientation relative to the applied field.

Figure 4 shows the results obtained when the T_2^* of the blood is reduced relative to that of the device by

In this example the black blood technique was used

WO 00/72032

PCT/GB00/01963


- 17 -

in vivo by accessing the right femoral artery of two pigs under general anaesthesia. For display of the vascular system the iron oxide contrast medium was administered intravenously at a dose of 5 mg Fe/kg bodyweight. Via the femoral approach, a 5F PTA catheter was introduced into the abdominal aorta. The 40x12 mm balloon was filled with a 7.7 mM Gd solution of GdDTPA-bismethyl-amide and imaged with spoiled GRE sequences. The experiment was repeated with a 6F catheter in which the guide-wire lumen was filled with the Gd-solution. Figures 7A (3D TR/TE/FA=5.2/1.2/40°) and 7B (2D TR/TE/FA=18/9/70°) show the resulting spoiled GRE in vivo images of the abdomen of the pig. Note the bright signal intensity of both vascular system and catheter balloon in the short-echo image. With TE=9 ms only the balloon (arrow) and blood in the intraperitoneal cavity from a preceding experiment remain visible.

Claims


7. A method as claimed in claim 5 wherein the T_2^* relaxation property of the blood is enhanced relative to that of said device and wherein T_2^* -weighted sequences are used and said device filled with paramagnetic material so that said device appears bright in said image, relative to the blood.
8. A method as claimed in any of claims 1 to 7 wherein said contrast agent is magnetic iron oxide blood pool contrast agent.
9. A method as claimed in any of claims 1 to 8 wherein said contrast agent comprises superparamagnetic iron oxide particles having on their surfaces degraded starch and optionally a material which inhibits opsonization.
10. A method as claimed in any of claims 1 to 9 wherein said device is chosen from catheters, balloons, optical fibres, guide wires, needles, biopsy needles, electrodes, electrode leads, implants, stents and stent grafts.
11. A method as claimed in any of claims 1 to 10 wherein said device is not marked with a magnetic susceptibility agent.
12. The use of a blood pool MR contrast agent for the manufacture of a parenterally administrable MR contrast medium for use in a method of surgery or therapy wherein an invasive device is inserted into the vasculature of a human or non human animal body or through vascularised tissue in said body and an MR image of at least a part of said body containing said device is generated, said method also comprising administering said contrast medium into the vasculature of said body whereby to facilitate visualisation of said device in said image.

catheter containing saline



A

catheter containing 10 mM Gd



B

FIG. 1




FIG. 2




FIG. 3




FIG. 4

3 / 4




FIG. 5a




FIG. 5b




FIG. 6a




FIG. 6b




FIG. 7a




FIG. 7b

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
are required to respond to a collection of information unless it contains

As a below named inventor, I hereby declare that:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled _____

the specification of which (Title of the Invention)

☒ was filed on (MM/DD/YYYY) 05/22/2000 as United States Application Number or PCT International

Application Number **PCT/GB00/01963** and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U S C 119(e) of any United States provisional application(s) listed below

| Application Number(s) | Filing Date (MM/DD/YYYY) | |
|-----------------------|--------------------------|--|
| | | <input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto. |

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)
Approved for use through 9/30/98 OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | |
|--------------------|---|
| DECLARATION | ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>1</u> of <u>1</u> |
|--------------------|---|

| | | | |
|--|-------|---|--------------------|
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle (if any)) | | Family Name or Surname | |
| <u>Atle</u> | | <u>Bjornerud</u> | |
| Inventor's Signature | | | Date <u>3/7/02</u> |
| Residence: City | State | Country | NO |
| Post Office Address <u>Olaf Bulls vei 46</u> | | | |
| Post Office Address <u>N-0765 Oslo Norway NOX</u> | | | |
| City | State | ZIP | Country |
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle (if any)) | | Family Name or Surname | |
| <u>Daniel</u> | | <u>Nanz</u> | |
| Inventor's Signature | | | Date |
| Residence: City | State | Country | CH |
| Post Office Address <u>Universitaetsspital Zuerich, MR-Zentrum, Raemistrasse</u> | | | |
| Post Office Address <u>CH-8091 Zuerich Switzerland</u> | | | |
| City | State | ZIP | Country |
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle (if any)) | | Family Name or Surname | |
| <u>Dominik</u> | | <u>Weishaupt</u> | |
| Inventor's Signature | | | Date |
| Residence: City | State | Country | CH |
| Post Office Address <u>Universitaetsspital Zuerich, MR-Zentrum, Raemistrasse 100</u> | | | |
| Post Office Address <u>CH-8091 Zuerich Switzerland</u> | | | |
| City | State | ZIP | Country |

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)
Approved for use through 9/30/98 OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

| | |
|--------------------|---|
| DECLARATION | ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>1</u> of <u>1</u> |
|--------------------|---|

| | | | |
|--|----------------|---|---------|
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle [if any]) | | Family Name or Surname | |
| Atle | | Bjernerud | |
| Inventor's Signature | | | Date |
| Residence: City | State | Country | NO |
| Post Office Address | | Nycomed Imaging AS, Nycoveien 1-2 | |
| Post Office Address | | N-0401 Oslo Norway | |
| City | State | ZIP | Country |
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle [if any]) | | Family Name or Surname | |
| Daniel | | Nanz | |
| Inventor's Signature | <i>D. Nanz</i> | | Date |
| Residence: City | State | Country | CH |
| Post Office Address | | Universitaetsspital Zuerich, MR-Zentrum, Raemistrasse | |
| Post Office Address | | CH-8091 Zuerich Switzerland CHX | |
| City | State | ZIP | Country |
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle [if any]) | | Family Name or Surname | |
| Dominik | | Weishaupt | |
| Inventor's Signature | | | Date |
| Residence: City | State | Country | CH |
| Post Office Address | | Universitaetsspital Zuerich, MR-Zentrum, Raemistrasse 100 | |
| Post Office Address | | CH-8091 Zuerich Switzerland | |
| City | State | ZIP | Country |

Burden Hour Statement This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231


+

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)
 Approved for use through 9/30/98 OMB 0651-0032
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | |
|--------------------|--|
| DECLARATION | ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>1</u> of <u>1</u> |
|--------------------|--|

| | | | |
|--|---|---|---------|
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle (if any)) | | Family Name or Surname | |
| Atle | | Bjernerud | |
| Inventor's Signature | | | Date |
| Residence: City | State | Country | NO |
| Post Office Address | Nycomed Imaging AS, Nycoveien 1-2 | | |
| Post Office Address | N-0401 Oslo Norway | | |
| City | State | ZIP | Country |
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle (if any)) | | Family Name or Surname | |
| Daniel | | Nanz | |
| Inventor's Signature | | | Date |
| Residence: City | State | Country | CH |
| Post Office Address | Universitaetsspital Zuerich, MR-Zentrum, Raemistrasse | | |
| Post Office Address | CH-8091 Zuerich Switzerland | | |
| City | State | ZIP | Country |
| Name of Additional Joint Inventor, if any: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | |
| Given Name (first and middle (if any)) | | Family Name or Surname | |
| Dominik | | Weishaupt | |
| Inventor's Signature |  | | Date |
| Residence: City | State | Country | CH |
| Post Office Address | Universitaetsspital Zuerich, MR-Zentrum, Raemistrasse 100 | | |
| Post Office Address | CH-8091 Zuerich Switzerland CHX | | |
| City | State | ZIP | Country |

Burden Hour Statement. This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ *Scanned copy is best available. Drawings fig. 2 to 7b
are very dark.*